Illumina: shedding light on genetics

Illumina, the genome sequencing specialist, is a leader in a thriving market. Long-term investors should buy now, says Mike Tubbs.

936_MW_P31_Companies

Illumina is well entrenched in the clinical diagnostic market

The science of who we are and how we got here has advanced in leaps and bounds in recent years. Take genome sequencing, the process of identifying the order of genetic letters' in an organism's DNA, or genetic code; reading' the genetic structure, essentially.

The whole human genome consists of three billion of these letters. It cost about $3bn and took 13 years for the very first decoding of a human genome to be completed in 2003.But today high-tech machines supplied by Illumina (Nasdaq: ILMN) do the same job for less than $1,000 in mere days.

An exciting field

For instance, plant and animal genomics speeds up the improvement of crops and farm animals originally carried out by selective breeding. Genome sequencing has identified many genetic markers in farm animals that are associated with desirable traits such as resistance to a particular disease. This facilitates breeding animals with this particular trait but without reductions in other desirable qualities.

Meanwhile, early detection of cancer can increase the chances of survival by a factor of ten. Since some tumour cell DNA (which is subtly different from normal cell DNA) circulates in the blood, sequencing of DNA collected from the blood can identify the presence of tumour cells.

Illumina, then, provides essential diagnostic and research tools for the growing life science and biotechnology sector. It is the clear global leader in genome sequencing, with around 75% of the overall market, a figure that continues to grow. More than 90% of sequenced genetic material is likely to have passed through an Illumina machine and there are 13,000 Illumina systems in active use globally.

Fund platform and research group Morningstar estimates that the genome sequencing market can grow to over $20bn, compared with Illumina's 2018 salesof $3.33bn.An important source of recurring revenue comes from the high-margin disposable products or equipment (such as reagents for testing that require replacing) that customers need to use with their sequencing systems. Usage increases both with the installed base and with increased machine use. Other services include training, servicing and consulting.

Protected from competition

Then there are regulatory hurdles for potential competitors, with Illumina's MiSeq platform the only genome sequencing instrument approved by America's Food and Drug Administration (FDA). The FDA is likely to want to add further regulations for sequencing in the clinical diagnostic market, entrenching Illumina's advantage.

For example, Illumina is likely to fund clinical trials to prove its instruments' worth for cancer screening tests. If these result in FDA approval, this will provide further barriers to entry for competitors. Cancer screening is a high-growth area since selection of the best treatment from the many new generation immuno-oncology drugs requires genetic profiles of tumours and patients.

Share price dip is a buying opportunity

Illumina (Nasdaq: ILMN)
Investment measureInvestment ratio
Share price$282.86p/e for 202037.7
Market cap$41.6bnNet cash$1.52bn
Next results (Q1) dueLate April 2019Yieldn/a
Recent results20172018Change
Turnover$2,752m$3,333m+21.1%
R&D$546m$623m+14.1%
Operating profit$687m$928m+35.1%
Earnings per share$4.00$5.72+43.0%

Illumina's technological lead is maintained both by its exceptionally high investment in R&D (18.7% of sales compared with Samsung's 7.2% or Google-parent Alphabet's 14.5%) and by bolt-on acquisitions.

In the past year Illumina has acquired Pacific Biosciences, a sequencing company, for $1.2bn and Edico Genome, a start-up data analysis company, for $100m. It has also partnered with Loxo Oncology on cancer diagnostics for solid tumours. Pacific Biosiences gives Illumina access to a specialised set of sequencing applications expected to grow to a value of $2.5bn a year by 2022.

Illumina has a strong balance sheet, a record of profitability and a history of shrewd capital allocation. Its forward price/earnings (p/e) ratio for 2019 is 39.5, high but a reflection of the impressive growth opportunities in the years ahead.

Growth expectations are based on the way genomic sequencing is creating new research applications and moving into many existing clinical diagnostic markets.

The shares, up 76% in the past five years, dipped after the 2018 results because of cautious guidance of 13%-14% revenue increase in 2019. They are down 19% from last September's peak a buying opportunity.

Recommended

Where to find inflation-resistant stocks
Investment strategy

Where to find inflation-resistant stocks

Terry Smith’s latest update contains some valuable pointers for investors looking to protect against inflation.
8 Aug 2022
A low-risk way to beat inflation
Share tips

A low-risk way to beat inflation

Demand for care-home places is strong and the sector should be able to raise prices ahead of costs, says Max King.
8 Aug 2022
Three stocks to provide income and growth in good times and bad
Share tips

Three stocks to provide income and growth in good times and bad

Professional investor Matthew Page of the Guinness Global Innovators fund picks three resilient stocks that should pay predictable dividends that grow…
5 Aug 2022
Share tips of the week – 5 August
Share tips

Share tips of the week – 5 August

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
5 Aug 2022

Most Popular

Are UK house prices finally heading for a crash?
House prices

Are UK house prices finally heading for a crash?

The latest house price figures show a fall of 0.1% in July. With interest rates rising, inflation hitting double figures and a recession on the cards,…
5 Aug 2022
Brace yourself for the return of rationing
Economy

Brace yourself for the return of rationing

Russia is turning off the cheap energy. That is already leading to belt-tightening, says Matthew Lynn. Who will suffer most, and which sectors will th…
5 Aug 2022
Zhao Weiguo: China’s No. 1 chip tycoon vanishes
People

Zhao Weiguo: China’s No. 1 chip tycoon vanishes

Zhao Weiguo rode a decades-long boom in China pursuing Beijing’s core industrial policy of semiconductor self-sufficiency. Then he fell foul of Xi Jin…
5 Aug 2022